Decitabine

MBG453 with hypomethylating agents in AML and high-risk MDS

Combining hypomethylating agents in AML

Significance of oral hypomethylating agents

hypomethylating agents in AML

Azacitidine and decitabine in treatment naive AML patients

Immune checkpoint inhibitors in MDS and AML

Onvansertib and decitabine in relapsed/refractory AML

Novel epigenetic drugs and their use in myeloid malignancies

Anti-TIM-3 antibody MBG453 + hypomethylating agents for high-risk MDS & AML

Rationale for 10-day decitabine with venetoclax for high-risk AML

Venetoclax with decitabine for high-risk AML and MDS

Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness

Decitabine and venetoclax for AML

Hypomethylating agents in MDS and AML

MDS novel agents & HMAs

The stages and treatments for myelodysplastic syndromes